Introduction: We examined the prevalence of cancer screening reported in 2015 among US adults, adjusted for important sociodemographic and access-to-care variables. By using data from the National Health Interview Survey (NHIS) for 2000 through 2015, we examined trends in prevalence of cancer screening that adhered to US Preventive Services Task Force screening recommendations in order to monitor screening progress among traditionally underserved population subgroups.
Methods: We analyzed NHIS data from surveys from 2000 through 2015 to estimate prevalence and trends in use of recommended screening tests for breast, cervical, colorectal, and prostate cancers. We used logistic regression and report predictive margins for population subgroups adjusted for various socioeconomic and demographic variables.
Results: Colorectal cancer screening was the only test that increased during the study period. We found disparities in prevalence of test use among subgroups for all tests examined. Factors that reduced the use of screening tests included no contact with a doctor in the past year, no usual source of health care, and no insurance coverage.
Conclusion: Understanding use of cancer screening tests among different population subgroups is vital for planning public health interventions with potential to increase screening uptake and reduce disparities in cancer morbidity and mortality. Overarching goals of Healthy People 2020 are to "achieve health equity, eliminate disparities, and improve the health of all groups." Adjusted findings for 2015, compared with previous years, show persistent screening disparities, particularly among the uninsured, and progress for colorectal cancer screening only.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093265 | PMC |
http://dx.doi.org/10.5888/pcd15.170465 | DOI Listing |
Liver Transpl
October 2024
Department of Internal Medicine, Mayo Clinic, Rochester MN.
Malignancy has a crucial impact on long-term survival after liver transplantation. There has been enhanced early detection rates with refined cancer screening and improved prognosis for many cancer diagnoses in the general population with the advent of targetted anti-cancer therapies. Similar advancements have not occurred in the transplant population over this same timeframe.
View Article and Find Full Text PDFDiscov Oncol
December 2024
Department Pulmonary and Critical Care Medicine, Tongde Hospital of Zhejiang Provincial, Hangzhou, China.
Lung squamous cell carcinoma (LUSC) is a subtype of non-small cell lung cancer. It has a grim prognosis for patients, primarily because the disease often remains asymptomatic in its early stages. As a result, it is frequently diagnosed at an advanced stage, limiting treatment options.
View Article and Find Full Text PDFDig Dis Sci
December 2024
Department of Medicine, University of Toronto, Toronto, Canada.
Background: Recent increases in colorectal cancer (CRC) incidence and mortality under age 50 have led the US to recommend starting screening at age 45 years instead of 50. Several other countries are now also reconsidering the age to start CRC screening.
Aims: To aid decision makers in making an informed decision about lowering the starting age of CRC screening in their jurisdictions.
Methods Mol Biol
December 2024
Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Optogenetic systems utilize genetically encoded light-sensitive proteins to control cellular processes such as gene expression and protein localization. Like most synthetic systems, generation of an optogenetic system with desirable properties requires multiple design-test-build cycles. A yeast optogenetic toolkit (yOTK) allows rapid assembly of optogenetic constructs using Modular Cloning, or MoClo.
View Article and Find Full Text PDFPLoS Pathog
December 2024
Virology Laboratory, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Human cytomegalovirus (HCMV) is a herpes virus with a long replication cycle. HCMV encoded long non-coding RNA termed RNA2.7 is the dominant transcript with a length of about 2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!